To evaluate the pharmacological properties of
cilostazol (CLZ), we examined its intraocular pressure (IOP) -lowering effect. CLZ is an inhibitor of Type III
phosphodiesterase that increases intracellular
cyclic AMP levels by restraining platelet aggregation, and has a potential protective effect against
atherosclerosis. We attempted to apply it for use as an
anti-glaucoma agent; however, the application of CLZ in the ophthalmic field is limited due to its poor water solubility. We attempted to enhance CLZ solubility using
2-hydroxypropyl-beta-cyclodextrin (
HPbetaCD). The solubility of CLZ increased with increasing
HPbetaCD concentrations, and 0.05% CLZ was dissolved in 10%
HPbetaCD. Moreover, fine particle
suspension of 0.5% CLZ in 5%
HPbetaCD (soluble CLZ: ca. 0.027%) were prepared using a Microfluidizer, an impact-type emulsifying comminution device. In an in vitro transcorneal penetration experiment through the rabbit cornea, the CLZ penetration rate was dependent on the CLZ content of the solutions and
suspensions. When a 0.05% CLZ
ophthalmic solution was instilled into a rabbit eye, the absorption rate constant for CLZ into an aqueous humor was 0.0059+/-0.001 min(-1), and the elimination rate constant was 0.048+/-0.024 min(-1). Also CLZ
ophthalmic solutions and fine particle
suspension were examined to for their ability to reduce enhanced intraocular pressure (IOP) of rabbits in a darkroom. The instillation of 0.05% CLZ
ophthalmic solutions and 0.5% CLZ fine particle
suspensions into rabbit eyes reduced the enhanced IOP. These results demonstrate that the instillation of CLZ
ophthalmic solutions and fine particle
suspensions may represent an effective anti-
glaucoma formulation.